Novavax Inc (NVAX NASDAQ) stock market data APIs
$8.3539
0.37(4.6%)
as of March 14, 2025
Novavax Inc Financial Data Overview
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Prev. Close
7.9884
Open
8.3539
High
8.5108
Low
7.9781
52 wk Range
3.81-23.8599
Market Cap
1 285 M
Shares Outstanding
161 M
Revenue
682 M
EPS
-0.52
Beta
2.91
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Novavax Inc data using free add-ons & libraries
Get Novavax Inc Fundamental Data
Novavax Inc Fundamental data includes:
- Net Revenue: 682 M
- EBITDA: -183 435 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-26
- EPS/Forecast: -0.5138
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Novavax Inc News
New
Need To Know: Analysts Just Made A Substantial Cut To Their Novavax, Inc. (NASDAQ:NVAX) Estimates
Market forces rained on the parade of Novavax, Inc. (NASDAQ:NVAX) shareholders today, when the analysts downgraded their forecasts for this year. Both revenue and earnings per share (EPS) forecasts we...
Novavax Announces Changes to Board of Directors
James Young, PhD retires as Chair of the Board, Margaret McGlynn, RPh, appointed John Shiver, PhD appointed to board of directors GAITHERSBURG, Md., March 11, 2025 /PRNewswire/ -- Novavax, Inc. (Nasd...
Novavax, Inc. (NASDAQ:NVAX) Shares Could Be 45% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Novavax fair value estimate is US$15.08 Novavax's US$8.33 share price signals that it might be 45% undervalued Our fair value estimate is 8.2%...
Novavax Inc (NVAX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial ...
Total Revenue: $682 million for the full year 2024. Product Sales: $190 million, primarily from US and European markets. Licensing, Royalties, and Other Revenue: $492 million for 2024. 4th Quarter Rev...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
